Pharmacokinetics of vanadium in humans after intravenous administration of a vanadium containing albumin solution

British Journal of Clinical Pharmacology

Volumn 55, Issue 3, 2003, Pages 241-245

  Heinemann, Günter ^a   Fichtl, Burckhard ^b   Vogt, Wolfgang ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Albumin; Electrothermal atomic absorption spectrometry (ETAAS); Half life; Parenteral infusion therapy; Pharmacokinetics; Ultra trace metal analysis; Vanadium

Indexed keywords

ALBUMIN; ALBUMIN 20% HUMAN; VANADIUM;

ADULT; AREA UNDER THE CURVE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INFUSION; DRUG PURITY; DRUG URINE LEVEL; ELECTROCHEMICAL ANALYSIS; HUMAN; HUMAN EXPERIMENT; MALE; PRIORITY JOURNAL; STEADY STATE; URINARY EXCRETION;

ADULT; ALBUMINS; AREA UNDER CURVE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; SPECTROPHOTOMETRY, ATOMIC; VANADIUM;

EID: 12244302194     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01711.x     Document Type: Article

References (35)

1. Nielsen FH, Uthus EO. The essentiality and metabolism of vanadium. In Vanadium in Biological Systems - Physiology and Biochemistry, ed. Chasteen ND. Dordrecht: Kluwer Academic Publishers, 1990; 51-62.
2. Nechay BR. Mechanisms of action of vanadium. Ann Rev Pharmacol Toxicol 1984; 24: 501-524.
3. Schaller KH, Triebig G. Vanadium. In Biological Indicators for the Assessment of Human Exposure to Industrial Chemicals, eds Alessio L, Berlin A, Boni M, Roi R. lspra: Commission of the European Communities, 1987; 78-93.
4. Willsky GR. Vanadium in the biosphere. In Vanadium in Biological Systems - Physiology and Biochemistry, ed. Chasteen ND. Dordrecht: Kluwer Academic Publishers, 1990; 1-24.
5. Sigel H, Sigel A, eds. Vanadium and its role in life, Vol. 31: Metal ions in biological systems. New York: Marcel Dekker, 1995; 1-779.
6. Nriagu JO, ed. Vanadium in the environment. Part 2: Health effects. Advances in Environmental Science and Technology. New York: John Wiley & Sons, 1998; 1-403.
7. Tracey AS, Crans DC, (eds). Vanadium Compounds: Chemistry, Biochemistry and Therapeutic Applications. ACS Symposium Series 711. Washington: American Chemical Society, 1998; 1-381.
8. Cohen N, Halberstam M, Shlimovich P, et al. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1995; 95: 2501-2509.
9. Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR. Metabolic effects of sodium rnetavanadate in humans with insulin-dependent diabetes mellitus: in vivo and in vitro studies. J Clin Endocrinol Metab 1995; 80: 3311-3320.
10. Boden G, Chen X, Ruiz J, van Rossum GD, Turco S. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism 1996; 45: 1130-1135.
11. Thompson KH, Orvig C. Design of vanadium compounds as insulin enhancing agents.J Chem Soc-Dalton Trans 2000; 17: 2885-2892.
12. Heinemann G, Vogt W. Quantification of vanadium in serum by electrothermal atomic absorption spectrometry. Clin Chem 1996; 42: 1275-1282.
13. Oberg SG, Parker RD, Sharma RP. Distribution and elimination of an intratracheally administered vanadium compound in the rat. Toxicology 1978; 11: 315-323.
14. Sabbioni E, Marafante E. Metabolic patterns of vanadium in the rat. Bioinorg Chem 1978; 9: 389-407.
15. Hansard SL, Ammerman CB, Henry PR, Patterson BW. Vanadium metabolism in sheep. III. Influence of dietary vanadium on kinetics of 48V administered orally or intravenously and comparison of compartmental and graphical models. J Animal Sci 1986; 62: 804-812.
16. Setyawati IA, Thompson KH, Yuen VG, et al. Kinetic analysis and comparison of uptake, distribution, and excretion of V-48-labeled compounds in rats. J Appl Physiol 1998; 84: 569-575.
17. Sakurai H, Sano H, Takino T, Yasui H. A new type of orally active insulin-mimetic vanadyl complex: bis (1-oxy-2-pyridinethiolato) oxovanadium (IV) with VO (S2O2) coordination mode. Chem Lett 1999; 9: 913-914.
18. Sakurai H, Sano H, Takino T, Yasui H. An orally active antidiabetic vanadyl complex, bis (1-oxy-2- pyridinethiolato) oxovanadium (IV), with VO (S2O2) coordination mode; in vitro and in vivo evaluations in rats. J Inorg Biochem 2000; 80: 99-105.
19. Yasui H, Takechi K, Sakurai H. Metallokinetic analysis of disposition of vanadyl complexes as insulin-mimetics in rats using BCM-ESR method. J Inorg Biochem 2000; 78: 185-196.
20. Derendorf H, Garrett ER. Pharmakokinetik. Stuttgart: Wiss-Verlagsges, 1987.
21. Ritschel WA. Handbook of Basic Pharmacokinetics. Hamilton, IL, USA: Drug Intelligence Publications, 1977; 1-370.
22. Allen L, Kimura K, MacKichan JJ, Ritschel WA. Manual of symbols, equations and definitions in pharmakokinetics. J Clin Pharmacol 1982; 22: 1S-23S.
23. Hopkins LL Jr, Tilton BE. Metabolism of trace amounts of vanadium 48 in rat organs and liver subcellular particles. Am J Physiol 1966; 211: 169-172.
24. Conklin AW, Skinner SC, Felten TL, Sanders CL. Clearance and distribution of intratracheally instilled vanadium compounds in the rat. Toxicol Lett 1982; 11: 199-203.
25. Kucera J, Simkova M, Lener J, et al. Vanadium determination in rat tissues and biological reference materials by neutron activation analysis. J Radioanal Nucl Chem 1990; 141: 49-59.
26. Heinemann G, Fichtl B, Mentler M, Vogt W. Binding of vanadate to human albumin in infusion solutions, to proteins in human fresh frozen plasma, and to transferrin. J Inorg Biochem 2002; 90: 38-42.
27. Chasteen ND, Grady JK, Holloway CE. Characterization of the binding, kinetics, and redox stability of vanadium (IV) and vanadium (V) protein complexes in serum. Inorg Chem 1986; 25: 2754-2760.
28. Purcell M, Neault JF, Malonga H, Arakawa H, Tajmir-Riahi HA. Interaction of human serum albumin with oxovanadium ions studied by FT-IR spectroscopy and gel and capillary electrophoresis. Can J Chem 2001; 79: 1415-1421.
29. Nielsen FH. Vanadium in mammalian physiology and nutrition. In Vanadium and its role in life, eds Sigel H, Sigel A. New York: Marcel Dekker, 1995; 543-573.
30. Stankiewicz PJ, Tracey AS. Stimulation of enzyme activity by oxovanadium complexes. In Vanadium and its role in life, eds Sigel H, Sigel A. New York: Marcel Dekker, 1995; 249-285.
31. Cannon JC, Chasteen ND. Nonequivalence of the metal binding sites in vanadyl-labeled human serum transferrin. Biochemistry 1975; 14: 4573-4577.
32. Sabbioni E, Marafante E, Pietra R, et al. The association of vanadium with the iron transport system in human blood as determined by gel filtration and neutron activation analysis. Proceedings of the International Symposium on Nuclear Activation Techniques in the Life Sciences, Wien, 1978; 179-192.
33. Harris WR, Carrano CJ. Binding of vanadate to human serum transferrin. J Inorg Biochem 1984; 22: 201-218.
34. Kent NL, McKane RA. The absorption and excretion of 'minor' elements by man. 1. Silver, gold, lithium, boron and vanadium. Biochem J 1941; 35: 837-844.
35. Willsky GR, Goldfine AB, Kostyniak PJ. Pharmacology and toxicology of oxovanadium species: Oxovanadium pharmacology. In Vanadium Compounds: Chemistry, Biochemistry, and Therapeutic Applications, eds Tracey, AS, Crans, DC. Washington: American Chemical Society, 1998; 278-296.